Andreas D. Hartkopf
About
Andreas D. Hartkopf is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Andreas D. Hartkopf has authored 169 papers receiving a total of 26.9k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Oncology, 86 papers in Cancer Research and 56 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas D. Hartkopf's work include Cancer Cells and Metastasis (51 papers), Breast Cancer Treatment Studies (49 papers) and Advanced Breast Cancer Therapies (41 papers). Andreas D. Hartkopf is often cited by papers focused on Cancer Cells and Metastasis (51 papers), Breast Cancer Treatment Studies (49 papers) and Advanced Breast Cancer Therapies (41 papers). Andreas D. Hartkopf collaborates with scholars based in Germany, United States and United Kingdom. Andreas D. Hartkopf's co-authors include Markus Wallwiener, Florin‐Andrei Taran, Sara Y. Brucker, Eva‐Maria Grischke, Christina B. Walter, Bernhard Krämer, Tanja Fehm, D. Wallwiener, Sara Y. Brucker and Markus Hahn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Bioinformatics.
In The Last Decade
Andreas D. Hartkopf
151 papers receiving 26.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Andreas D. Hartkopf Germany | 24 | 19.3k | 9.0k | 7.1k | 6.8k | 5.5k | 169 | 26.9k | ||
| Florin‐Andrei Taran Germany | 23 | 18.6k 1.0× | 8.9k 1.0× | 6.8k 1.0× | 6.6k 1.0× | 4.9k 0.9× | 77 | 26.3k | ||
| Christina B. Walter Germany | 6 | 18.1k 0.9× | 8.9k 1.0× | 6.7k 0.9× | 6.3k 0.9× | 4.5k 0.8× | 13 | 25.0k | ||
| Eva‐Maria Grischke Germany | 24 | 20.6k 1.1× | 9.0k 1.0× | 7.6k 1.1× | 8.4k 1.2× | 5.5k 1.0× | 126 | 29.4k | ||
| David P. Carbone United States | 78 | 13.6k 0.7× | 9.1k 1.0× | 10.9k 1.5× | 6.5k 1.0× | 4.5k 0.8× | 413 | 26.9k | ||
| Jeffrey A. Sosman United States | 73 | 16.2k 0.8× | 6.9k 0.8× | 15.5k 2.2× | 8.3k 1.2× | 5.0k 0.9× | 347 | 28.5k | ||
| Omid Hamid United States | 68 | 21.3k 1.1× | 9.8k 1.1× | 8.0k 1.1× | 4.9k 0.7× | 1.9k 0.3× | 414 | 26.3k | ||
| Timothy A. Chan United States | 77 | 10.4k 0.5× | 4.5k 0.5× | 9.4k 1.3× | 5.5k 0.8× | 5.2k 0.9× | 243 | 22.7k | ||
| Catherine Sautès‐Fridman France | 79 | 14.6k 0.8× | 15.3k 1.7× | 7.8k 1.1× | 5.2k 0.8× | 3.7k 0.7× | 251 | 27.8k | ||
| Sherene Loi Australia | 85 | 24.0k 1.2× | 7.5k 0.8× | 9.5k 1.3× | 10.9k 1.6× | 11.0k 2.0× | 442 | 34.8k | ||
| Padmanee Sharma United States | 63 | 20.0k 1.0× | 13.9k 1.5× | 6.5k 0.9× | 5.8k 0.8× | 2.9k 0.5× | 257 | 28.5k |
Countries citing papers authored by Andreas D. Hartkopf
Since
Specialization
Citations
This map shows the geographic impact of Andreas D. Hartkopf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas D. Hartkopf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas D. Hartkopf more than expected).
Fields of papers citing papers by Andreas D. Hartkopf
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andreas D. Hartkopf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas D. Hartkopf. The network helps show where Andreas D. Hartkopf may publish in the future.
Co-authorship network of co-authors of Andreas D. Hartkopf
This figure shows the co-authorship network connecting the top 25 collaborators of Andreas D. Hartkopf. A scholar is included among the top collaborators of Andreas D. Hartkopf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas D. Hartkopf. Andreas D. Hartkopf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dannehl, Dominik, et al.. (2025). Oral Maintenance Therapy in Early Breast Cancer—How Many Patients Are Potential Candidates?. Cancers. 17(1). 145–145.
2.
Granai, Massimo, André Koch, Dominik Dannehl, et al.. (2024). Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 485(4). 631–642.
3.
Preibsch, Heike, André Koch, Laimdota Zizmare, et al.. (2024). Image‐guided metabolomics and transcriptomics reveal tumour heterogeneity in luminal A and B human breast cancer beyond glucose tracer uptake. Clinical and Translational Medicine. 14(2). e1550–e1550.
4.
Lüftner, Diana, Florian Schuetz, Andreas Schneeweiß, et al.. (2024). Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study. International Journal of Cancer. 155(1). 128–138.
5.
Krell, Jonathan, John McGrane, Andreas D. Hartkopf, et al.. (2024). Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression. Future Oncology. 20(40). 3409–3419.
6.
Graeser, Monika, Oleg Gluz, Peter Schmid, et al.. (2024). Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.. Journal of Clinical Oncology. 42(16_suppl). 590–590.
7.
Dannehl, Dominik, Kerstin Pfister, Brigitte Rack, et al.. (2024). Abstract PO5-16-11: Novel antibody-drug-conjugates in clinical routine: adherence, efficacy and tolerability - real-world data from German breast centers. Cancer Research. 84(9_Supplement). PO5–16.
8.
Harbeck, Nadia, Michael Braun, Oleg Gluz, et al.. (2024). Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.. Journal of Clinical Oncology. 42(16_suppl). TPS631–TPS631.
9.
Hagelstein, Ilona, André Koch, Jonas S. Heitmann, et al.. (2024). Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome. International Journal of Molecular Sciences. 25(7). 4126–4126.
10.
Hartkopf, Andreas D.. (2023). Immuntherapie in der gynäkologischen Onkologie und Senologie. 56(8). 557–565.
11.
Krell, Jonathan, John McGrane, Anjana Anand, et al.. (2022). 2022-RA-1505-ESGO Ovarian cancer retrospective European (O’CaRE) observational study: analysis of first-line (1L) outcomes in patients with ovarian cancer (OC) stratified by number of risk factors for progression. International Journal of Gynecological Cancer. 32. A344–A344.
12.
Gregorio, Amelie de, Wolfgang Janni, Thomas W. P. Friedl, et al.. (2022). The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer. 126(12). 1715–1724.
13.
Koch, André, Berthold Gierke, Annette Staebler, et al.. (2022). A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer. Cancers. 14(12). 2895–2895.
14.
Engler, Tobias, Heike Müller, Eva‐Maria Grischke, et al.. (2022). Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre. Geburtshilfe und Frauenheilkunde. 83(6). 694–701.
15.
Helms, G, Andreas D. Hartkopf, Heike Preibsch, et al.. (2021). Evaluation of sonographic detectability of different markers within an in vitro simulation model of the axilla. Archives of Gynecology and Obstetrics. 304(3). 839–848.
16.
Deutsch, Thomas M., Sabine Riethdorf, Carlo Fremd, et al.. (2020). HER2-targeted therapy influences CTC status in metastatic breast cancer. Breast Cancer Research and Treatment. 182(1). 127–136.
17.
Rensburg, Ruan van, Ellen Honisch, Martina Rudelius, et al.. (2019). EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Molecular Cancer Research. 18(2). 278–286.
18.
Taran, Florin‐Andrei, et al.. (2018). Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy. Archives of Gynecology and Obstetrics. 297(3). 785–790.
19.
Wallwiener, Markus, Andreas D. Hartkopf, Sabine Riethdorf, et al.. (2015). The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer. 15(1). 403–403.
20.
Friedl, Thomas W. P., Fabienne Schochter, Christoph Scholz, et al.. (2015). Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Archives of Gynecology and Obstetrics. 293(2). 271–281.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Florin‐Andrei Taran Breakdown of academic impact, for papers by Christina B. Walter Breakdown of academic impact, for papers by Eva‐Maria Grischke Breakdown of academic impact, for papers by David P. Carbone Breakdown of academic impact, for papers by Jeffrey A. Sosman Breakdown of academic impact, for papers by Omid Hamid Breakdown of academic impact, for papers by Timothy A. Chan Breakdown of academic impact, for papers by Catherine Sautès‐Fridman Breakdown of academic impact, for papers by Sherene Loi Breakdown of academic impact, for papers by Padmanee Sharma